| Compounds | Topics | Title | Date |
|---|---|---|---|
| WIN55,AM6545 | weight loss,obesity in mice via experiment | Cannabinoid CB1 Receptors Inhibit Gut-Brain Satiation Signaling in Diet-Induced Obesity | Mar 2019 |
|
Action Pathway: CB1 Collectively, these results provide evidence that hyperphagia associated with DIO is driven by a mechanism that includes CB1R-mediated inhibition of gut-brain satiation signaling. | |||
| AM6545 | obesity in mice | Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity | Aug 2010 |
|
Action Pathway: CB1 Here we have demonstrated that a CB1R neutral antagonist largely restricted to the periphery does not affect behavioral responses mediated by CB1R in the brains of mice with genetic or diet-induced obesity, but it does cause weight-independent improvements in glucose homeostasis, fatty liver, and plasma lipid profile | |||
| AM6545 | obesity,appetite supress in vitro | A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents | Oct 2010 |
| Peripherally active, cannabinoid receptor antagonists with limited brain penetration may be useful agents for the treatment of obesity and its complications. | |||
| AM6545 | obesity,appetite supress in rats via experiment | THE NOVEL CANNABINOID CB1 ANTAGONIST AM6545 SUPPRESSES FOOD INTAKE AND FOOD-REINFORCED BEHAVIOR | Aug 2010 |
|
Ingestion Method: 16mg/kg AM6545 also produced a strong suppression of the intake of high carbohydrate and high fat diets in the same dose range, but only produced a mild suppression of lab chow intake at the highest dose (16.0 mg/kg). Although AM6545 did not affect food handling, it did reduce time spent feeding and feeding rate. Taken together, these results suggest that AM6545 is a compound that warrants further study as a potential appetite suppressant drug. | |||